U.S. Markets close in 28 mins
  • S&P 500

    4,545.27
    +9.08 (+0.20%)
     
  • Dow 30

    35,565.54
    -43.80 (-0.12%)
     
  • Nasdaq

    15,208.50
    +86.82 (+0.57%)
     
  • Russell 2000

    2,293.77
    +4.00 (+0.17%)
     
  • Gold

    1,784.90
    0.00 (0.00%)
     
  • EUR/USD

    1.1627
    -0.0026 (-0.2209%)
     
  • 10-Yr Bond

    1.6760
    +0.0400 (+2.44%)
     
  • Vix

    15.18
    -0.31 (-2.00%)
     
  • GBP/USD

    1.3784
    -0.0042 (-0.3019%)
     
  • USD/JPY

    113.9680
    -0.3610 (-0.3158%)
     
  • BTC-USD

    63,394.82
    -3,072.43 (-4.62%)
     
  • CMC Crypto 200

    1,500.96
    -33.69 (-2.20%)
     
  • FTSE 100

    7,190.30
    -32.80 (-0.45%)
     
  • Nikkei 225

    28,708.58
    -29,255.55 (-100.00%)
     

Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in two virtual panel discussions and virtual 1x1 meetings at the William Blair Biotech Focus Conference 2021. Details are as follows:

William Blair Biotech Focus Conference 2021
Date: Wednesday, July 14
Panel: Developing Therapies for the Next Immuno-Oncology Targets
Time: 2:10-3:10 p.m.

Date: Thursday, July 15
Panel: Non-Viral Drug Delivery
Time: 2:00-2:45 p.m.

Live webcasts of the virtual panel discussions will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. Archived replays will be available for approximately 30 days following the events.

About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx™ Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

CONTACT: Investor Contact: Christopher Taylor VP, Investor Relations and Corporate Communications T: 617-949-4220 E: investor@codiakbio.com Media Contact: Lindy Devereux Scient PR T: 646-515-5730 E: media@codiakbio.com